Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Patients with urologic cancers are more likely to attempt suicide, highlighting the need for increased psychiatric intervention for these patients at an earlier stage, according to findings presented at the European Association of Urology (EAU) 2018 Congress.
The androgen receptor inhibitor apalutamide prolonged metastasis-free survival (MFS) by approximately 2 years in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastatic disease, according to findings of the SPARTAN* trial.
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.
Researchers have developed a new polygenic hazard score, which has been validated by an independent dataset, for assessing personalized genetic risk that can predict age at onset of aggressive prostate cancer, reports a study.
Treatment with enzalutamide has maintained its antitumour activity in patients with hormone-naïve prostate cancer at 3 years, according to a recent study. In addition, overall bone mineral density, global health status and safety results are comparable to those at 2 years.
Compared with the anterior approach to the prostate, Retzius-sparing-robot-assisted radical prostatectomy is faster, allows a shorter catheterization time, and delivers better continence results at 4 weeks, with most patients being pad-free or needing just a single pad a day, a recent study has shown.
Enzalutamide, compared with bicalutamide, is effective in improving clinical outcomes regardless of age in chemotherapy-naïve men with metastatic castration-resistant prostate cancer, reports a recent study.
Systolic blood pressure appears to have a strong association with aneurysmal subarachnoid haemorrhage (aSAH) but not with unruptured intracranial aneurysm (UIA), whereas current smoking and female sex are risk factors for both conditions, a study has found.